The Pfizer Fellowship Grant for Transthyretin Cardiac Amyloidosis is a competitive grant initiative aimed at advancing the professional development of healthcare professionals specializing in the diagnosis and management of ATTR cardiac amyloidosis. This grant is dedicated to enhancing academic and clinical understanding of the disease through research and education. Offered to U.S.-based academic institutions, the program supports fellowship roles for Cardiologists or Heart Failure Advanced Practice Providers, emphasizing a balance of clinical practice, research, and educational outreach. The grant ensures that the supported activities are independent of Pfizer’s commercial interests, focusing on fostering substantial advancements in the field of cardiac health.